Efficacy and tolerability of budesonide/formoterol added to tiotropium compared with tiotropium alone in patients with severe or very severe COPD: A randomized, multicentre study in East Asia

Respirology

Volumn 21, Issue 1, 2016, Pages 119-127

  Lee, Sang Do ^a   Xie, Can Mao ^b   Yunus, Faisal ^e   Itoh, Yohji ^c   Ling, Xia ^c   Yu, Wai Cho ^d   Kiatboonsri, Sumalee ^f  

^a University of Ulsan College of Medicine   (South Korea)

^b THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c ASTRAZENECA   (United Kingdom)

^d PRINCESS MARGARET HOSPITAL   (Hong Kong)

^e UNIVERSITY OF INDONESIA   (Indonesia)

^f MAHIDOL UNIVERSITY   (Thailand)

Author keywords

budesonide formoterol; chronic obstructive pulmonary disease; East Asia; tiotropium

Indexed keywords

BUDESONIDE PLUS FORMOTEROL; TIOTROPIUM BROMIDE; BRONCHODILATING AGENT;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED STUDY; COUGHING; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; EAST ASIAN; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; PHASE 4 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; TREATMENT DURATION; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; DRUG EFFECTS; DRUG MONITORING; FAR EAST; MIDDLE AGED; PROCEDURES; PSYCHOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECURRENT DISEASE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

AGED; BRONCHODILATOR AGENTS; BUDESONIDE, FORMOTEROL FUMARATE DRUG COMBINATION; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; DRUG THERAPY, COMBINATION; FAR EAST; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SYMPTOM FLARE UP; TIOTROPIUM BROMIDE; TREATMENT OUTCOME;

EID: 84951039756     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12646     Document Type: Article

References (27)

1. Global initiative for chronic Obstructive Lung Disease (GOLD). 2014. Global Strategy for the Diagnosis, Management, and Prevention of COPD. www.goldcopd.org. Accessed: 03 March 2014.
2. Ko FW, Hui DS, Lai CK,. Worldwide burden of COPD in high- and low-income countries. Part III. Asia-Pacific studies. Int. J. Tuberc. Lung Dis. 2008; 12: 713-717.
3. Tan WC, Ng TP,. COPD in Asia: where East meets West. Chest 2008; 133: 517-527.
4. Tan WC, Seale P, Ip M, Shim YS, Chiang CH, Ng TP, Abisheganadan J, Charoenratanakul S, DeGuia T, Mahayiddin A, et al. Trends in COPD mortality and hospitalizations in countries and regions of Asia-Pacific. Respirology 2009; 14: 90-97.
5. Tam WW, Wong TW, Wong AH, Hui DS,. Effect of dust storm events on daily emergency admissions for respiratory diseases. Respirology 2012; 17: 143-148.
6. Oh YM, Bhome AB, Boonsawat W, Gunasekera KD, Madegedara D, Idolor L, Roa C, Kim WJ, Kuo HP, Wang CH, et al. Characteristics of stable chronic obstructive pulmonary disease patients in the pulmonology clinics of seven Asian cities. Int. J. Chron. Obstruct. Pulmon. Dis. 2013; 8: 31-39.
7. Chan-Yeung M, Ait-Khaled N, White N, Ip MS, Tan WC,. The burden and impact of COPD in Asia and Africa. Int. J. Tuberc. Lung Dis. 2004; 8: 2-14.
8. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H,. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 22: 912-919.
9. Sharafkhaneh A, Southard JG, Goldman M, Uryniak T, Martin UJ,. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. Respir. Med. 2012; 106: 257-268.
10. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H,. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 21: 74-81.
11. Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Molken MP, Beeh KM, Rabe KF, Fabbri LM,. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N. Engl. J. Med. 2011; 364: 1093-1103.
12. Welte T, Miravitlles M, Hernandez P, Eriksson G, Peterson S, Polanowski T, Kessler R,. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2009; 180: 741-750.
13. Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, Balter M, O'Donnell D, McIvor A, Sharma S, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann. Intern. Med. 2007; 146: 545-555.
14. Jung KS, Park HY, Park SY, Kim SK, Kim YK, Shim JJ, Moon HS, Lee KH, Yoo JH, Lee SD,. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respir. Med. 2012; 106: 382-389.
15. Meguro MJ, Jones PW,. Validity and repeatability of a shortened SGRQ for COPD (SGRQ-C). Eur. Respir. J. 2005; 26: 383.
16. Leidy NK, Rennard SI, Schmier J, Jones MK, Goldman M,. The breathlessness, cough, and sputum scale: the development of empirically based guidelines for interpretation. Chest 2003; 124: 2182-2191.
17. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA,. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 157: 1418-1422.
18. Zhou YM, Wang XP, Zeng XY, Qiu R, Xie JF, Liu SM, Zheng JP, Zhong NS, Ran PX,. [Theophylline in the treatment of chronic obstructive pulmonary disease: a randomized, double-blind, placebo-controlled study]. Zhonghua Jie He He Hu Xi Za Zhi. 2006; 29: 577-582.
19. Fukuchi Y, Samoro R, Fassakhov R, Taniguchi H, Ekelund J, Carlsson LG, Ichinose M,. Budesonide/formoterol via Turbuhaler® versus formoterol via Turbuhaler® in patients with moderate to severe chronic obstructive pulmonary disease: phase III multinational study results. Respirology 2013; 18: 866-873.
20. Mittmann N, Hernandez P, Mellstrom C, Brannman L, Welte T,. Cost effectiveness of budesonide/formoterol added to tiotropium bromide versus placebo added to tiotropium bromide in patients with chronic obstructive pulmonary disease: Australian, Canadian and Swedish healthcare perspectives. Pharmacoeconomics 2011; 29: 403-414.
21. Nielsen R, Kankaanranta H, Bjermer L, Lange P, Arnetorp S, Hedegaard M, Stenling A, Mittmann N,. Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Respir. Med. 2013; 107: 1709-1721.
22. Tashkin DP, Rennard SI, Martin P, Ramachandran S, Martin UJ, Silkoff PE, Goldman M,. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs 2008; 68: 1975-2000.
23. Calverley PM, Similowski T, Eriksson GS, Jenkins CR, Anzueto A, Make BJ, Fageras M, Persson A, Postma D,. Time dependency of exacerbations and study drop-out among patients with moderate, severe, and very severe COPD. Am. J. Respir. Crit. Care Med. 2013; 187: A4278. Abstr.
24. Larsson K, Janson C, Lisspers K, Jorgensen L, Stratelis G, Telg G, Stallberg B, Johansson G,. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study. J. Intern. Med. 2013; 273: 584-594.
25. Blais L, Forget A, Ramachandran S,. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence. Clin. Ther. 2010; 32: 1320-1328.
26. Johansson G, Janson C, Stallberg B, Lisspers K, Stratelis G, Jorgensen L, Larsson K,. COPD exacerbations and pneumonia on triple therapy (fixed ICS/LABA combinations and tiotropium). Does the choice of ICS/LABA matter? Am. J. Respir. Crit. Care Med. 2013; 187: A2442. Abstr.
27. Wedzicha JA, Decramer M, Ficker JH, Niewoehner DE, Sandstrom T, Taylor AF, D'Andrea P, Arrasate C, Chen H, Banerji D,. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir. Med. 2013; 1: 199-209.